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Commonly used abbreviations 
BNP:   Brain-type natriuretic peptide 
BCIS-JS:  British Cardiovascular Intervention Society jeopardy score 
CABG:   Coronary artery bypass graft surgery 
EF:   Ejection fraction 
HF:   Heart failure 
ICD:   Implantable cardioverter defibrillator 
ICM:   Ischemic cardiomyopathy 
LV:   Left ventricular 
MRI:   Magnetic resonance imaging 
MI:   Myocardial infarction 
OMT:   Optimal medical therapy 
PCI:   Percutaneous coronary intervention 
 
 
Condensed Abstract 
Heart failure (HF) due to coronary artery disease is associated with significant 
mortality and morbidity. REVIVED-BCIS2 is a prospective, multi-center, open-
label, randomized controlled trial that addresses the hypothesis that PCI in 
combination with optimal medical therapy (OMT) will reduce all-cause death 
and hospitalization for HF compared to a strategy of OMT alone in patients with 
a left ventricular ejection fraction (LVEF) ≤35%, extensive coronary disease and 
demonstrable myocardial viability. Change in LVEF is a major secondary 
endpoint. Follow-up will be for at least 2 years from randomization. 400 of 700 
patients have been enrolled to date. 
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Abstract 
 
Background: Ischemic cardiomyopathy (ICM) is the commonest cause of heart 
failure (HF) and is associated with significant mortality and morbidity. Surgical 
revascularization has been shown to improve long-term outcomes in some 
patients, but surgery itself carries a major early hazard. Percutaneous coronary 
intervention (PCI) may allow a better balance between risk and benefit. 
 
Objectives: Evaluate whether PCI in combination with optimal medical therapy 
(OMT) will reduce all-cause death and hospitalization for HF compared to a 
strategy of OMT alone. 
 
Methods: REVIVED-BCIS2 is a prospective, multi-center, open- label, 
randomized controlled trial, funded by the National Institute for Health Research 
in the United Kingdom. Follow-up will be for at least 2 years from randomization. 
Secondary outcomes include left ventricular (LV) ejection fraction (EF), quality 
of life scores, appropriate Implantable Cardioverter Defibrillator therapy and 
acute myocardial infarction. Patients with LVEF ≤35%, extensive coronary 
disease and demonstrable myocardial viability are eligible for inclusion and 
those with a myocardial infarction within 4 weeks, decompensated HF or 
sustained ventricular arrhythmias within 72 hours are excluded. A trial of 700 
patients has more than 85% power to detect a 30% relative reduction in hazard.  
 
Results: 400 patients have been enrolled to date. 
 
Conclusion: International guidelines do not provide firm recommendations on 
the role of PCI in managing severe ICM, due to lack of robust evidence. REVIVED- 
BCIS2 will provide the first randomized data on the efficacy and safety of PCI in 
ICM and has the potential to inform guidelines pertaining to both 
revascularization and HF. 
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Introduction 
The prevalence of heart failure (HF) due to left ventricular (LV) systolic 
dysfunction is increasing (1) and ischemic cardiomyopathy (ICM) accounts for 
approximately 60% of all HF cases(2, 3). Pathophysiologically, ICM encompasses 
a spectrum of sequelae of coronary disease, including myocardial infarction (MI) 
(which leads to irreversible fibrosis) and hibernation (a potentially reversible 
adaptation to repetitive ischemia), which often co-exist in a given patient and 
can both lead to adverse remodeling and LV dysfunction. Hibernation was a term 
coined nearly 40 years ago to describe the reversal of remodeling and 
augmentation of systolic function following surgical coronary artery bypass 
grafting (CABG), noted in patients with chronic stable angina and severe LV 
dysfunction(4). While subsequent observational studies of surgical 
revascularization appeared to confirm the existence of hibernation(5, 6), until 
recently, this had not been adequately assessed in a randomized study.  
 
The seminal Surgical Treatment for Ischemic Heart Failure (STICH) trial, the only 
randomized evaluation of CABG for ICM to date, enrolled patients with a LV 
ejection fraction (EF) ≤35%.  At a median of 4.6 years, the primary outcome, all-
cause mortality, was not significantly different between patients treated with 
optimal medical therapy (OMT) alone compared to those assigned to CABG 
surgery (41% vs. 36%, hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.72 
to 1.04, p=0.12)(7). Mortality in the first 30 days was significantly higher in the 
surgical group (4% vs. 1%, HR 3.12, 95% CI 1.33 – 7.32, p=0.009). This finding is 
in keeping with the known association between mortality and LV dysfunction 
following CABG surgery(8). The early hazard of CABG may have negated the 
benefits of revascularization, which become gradually manifest in those who 
survive the complications of surgery. The Surgical Treatment for Ischemic Heart 
Failure Extension Study (STICHES) reported longer-term mortality data from the 
STICH trial.  At median follow up of approximately 10 years, 59% of patients 
assigned to CABG died versus 66% in the medical therapy group (HR 0.84; 95% 
CI 0.73-0.97; p=0.02)(9). Death from cardiovascular causes and several pre-
specified composite secondary endpoints also occurred less often in the CABG 
group. The critical balance between safety and efficacy is also borne out when 
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examining the impact of age on treatment effect in STICH. Long-term survival 
benefit was most apparent in the youngest patients enrolled in the trial (in 
whom the risks of peri-procedural mortality and morbidity are lowest) and this 
benefit diminished with increasing age(10).  
 
Given the lower procedural risks associated with percutaneous coronary 
intervention (PCI), it has the potential to allow the benefits of revascularization 
to be realized with fewer complications than CABG surgery, but this assertion is 
yet to be tested in a randomized trial. Table 1 summarizes randomized and 
observational studies of revascularization versus medical therapy published in 
the past 15 years and includes the proportion of patients treated by PCI. It 
should be noted that the risk of longer-term complications, such as restenosis 
and late stent thrombosis, in this population who tend to have complex coronary 
disease and multiple comorbidities, is largely unknown. While numerous 
comparisons have been made between PCI and CABG in patients with 
symptomatic coronary disease, most of the large randomised trials excluded 
patients with impaired LV function. Less than 2% of all patients included in the 
largest randomised controlled trial comparing PCI with CABG, SYNTAX, had 
significant LV impairment (EF<30%) at baseline(11). We reported outcomes of 
PCI in 301 patients with severe ICM (mean EF 24%), showing 30-day, 6-month 
and 4 year mortality rates of 1.3%, 6% and 33%, respectively(12, 13). These 
results appear to compare favourably with the surgical data, but as these are not 
matched cohorts, further comparison is not possible. On the other hand, the 
degree of LV impairment is a known determinant of adverse outcome even in 
patients undergoing PCI(14) and whether this modality of revascularization 
would offer incremental prognostic benefit, over and above contemporary HF 
medication and device therapy, is unclear. A recent meta-analysis of 
observational data suggests that CABG may offer superior outcomes compared to 
PCI, with either modality being preferable to medial therapy alone(15). The 2014 
ESC guidelines for revascularisation make a class IIb recommendation (with a 
level of evidence C) for PCI, in the presence of viable myocardium, where surgery 
is not indicated(16).  REVIVED-BCIS2 is the first randomised comparison of 
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percutaneous revascularisation (with OMT) versus OMT alone in patients with 
LV dysfunction and viable myocardium. 
 
Trial hypotheses and outcome measures 
The principle hypothesis of REVIVED_BCIS2 is that PCI in combination with OMT 
will improve event-free survival in patients with ICM and viable myocardium, 
compared to a strategy of OMT alone. The main secondary hypothesis is that PCI 
will improve LV systolic function in this cohort compared to OMT alone. The 
primary outcome is a composite endpoint of all-cause death or hospitalization 
due to HF, over the entire duration of the trial. Patients will be followed up for at 
least 2 years from randomization (expected range 2 to 8.5 years). The major 
secondary outcome is LVEF, assessed by echocardiography, 6 and 12 months 
from randomization. Other outcome measures include cardiovascular death, all-
cause death, hospitalization due to HF, acute MI, appropriate Implantable 
Cardioverter Defibrillator (ICD) therapy, quality of life scores (Kansas City 
Cardiomyopathy Questionnaire and EuroQol EQ-5D-5L), New York Heart 
Association (NYHA) functional class, unplanned further revascularization, 
Canadian Cardiovascular Society (CCS) angina class, health resource use, serial 
Troponin T or I levels, serial Brain-type Natriuretic Peptide (BNP or NT-proBNP) 
levels and the incidence of major bleeding. Definitions of outcome measures are 
detailed in table 2. 
 
Study Population 
Individuals with all of the following characteristics will be eligible for inclusion:  
severe LV dysfunction (EF≤35%), extensive coronary disease and demonstrable 
viability in at least 4 dysfunctional myocardial segments(17) that can be 
revascularized by PCI. As this is a trial assessing the prognosis of patients with 
LV dysfunction, those with a spectrum of HF symptoms (NHYA I to IV) will be 
enrolled.  
 
LVEF is assessed by the biplane Simpson’s Rule/3D echocardiography or by 
Magnetic Resonance Imaging (MRI). If there has been a recent clinical diagnosis 
of MI (MI), the imaging study is performed at least 4 weeks after the MI. 
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Extensive coronary disease is defined as a British Cardiovascular Intervention 
Society myocardial jeopardy score (BCIS-JS)(18) of at least 6 (the maximum 
possible score is 12; a calculation tool is included in the supplementary 
appendix). The BCIS-JS can be applied to patients with or without previous 
bypass grafts; for illustration, patients who do not have bypass grafts will have a 
BCIS-JS ≥6 if they have significant left main, proximal LAD or at least proximal 
two-vessel disease. Myocardial viability  is characterized using the AHA 17-
segment model and can be assessed using any recognised modality, including 
MRI, Dobutamine Stress Echocardiography (DSE), Single Photon Emission 
Computerised Tomography (SPECT) or Positron Emission Tomography (PET). 
 
Trial exclusion criteria are a MI within 4 weeks of randomization (this is a 
clinical definition as adjudicated by recruiting centres); acutely decompensated 
HF requiring treatment with inotropes/ ventilation/MCS within 72 hours of 
randomization; sustained ventricular tachycardia/fibrillation (VT/VF) or 
appropriate ICD discharges within 72 hours of randomisation; valve disease 
deemed by the local heart team to require imminent intervention; any 
contraindications to PCI; age <18 yrs (there is no upper age limit); estimated 
glomerular filtration rate < 25 ml/min/1.73m2, unless established on dialysis; 
pregnancy; previous enrolment in REVIVED-BCIS2 or current enrolment in other 
trial that may affect REVIVED-BCIS2 outcome data and life expectancy < 1 year 
due to non-cardiac pathology. 
 
It is anticipated that some eligible candidates (such as those with severe limiting 
angina) will be considered for revascularization on clinical grounds, at the 
discretion of the responsible clinician and in accordance with the wishes of the 
patients. Similarly, in some cases, eligible patients may be offered coronary 
artery bypass surgery, including those thought to benefit from adjunctive 
surgical procedures (like valve repair/replacement or left ventricular 
reconstruction) or those whose coronary anatomy is considered by the local 
team to be more amenable to surgical rather than percutaneous 
revascularization.  These patients will not be enrolled in the trial but the 
screening log (see below) will capture such exclusions. 
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Trial design, conduct and organization 
REVIVED-BCIS2 is a prospective randomized controlled trial, conducted across 
30-35 centers in the United Kingdom. Once the principal investigator at each site 
confirms the eligibility of a patient and written informed consent is obtained, 
randomization is carried out via an online web-based system. Randomization of 
the treatment assignment is stratified by center using randomly permuted 
blocks of varying size, with 1:1 allocation between the PCI and OMT arms. Given 
the nature of PCI, this is an open-label trial, but researchers adjudicating and 
analysing trial outcomes will be blinded to treatment assignment. Figure 1 
summarizes recruitment and study flow. 
 
The trial is sponsored by King’s College London, UK and funded by the UK 
Department of Health via the National Institute for Health Research (NIHR) 
(Health Technology Assessment project 10/57/67) with oversight by a Trial 
Steering Committee (TSC) that meets pre-specified independence criteria 
(Figure 3).  A Data and Safety Monitoring Committee (DSMC) has been convened 
and a DSMC charter developed, which includes details of the meeting schedule 
and stopping guidelines.  The DSMC are independent of the trial team and report 
directly to the TSC. The Clinical Trials Unit (CTU) at the London School of 
Hygiene and Tropical Medicine coordinate and monitor all aspects of the trial. 
The trial is officially endorsed by the British Cardiovascular Intervention Society 
(BCIS) and hence is referred to as REVIVED-BCIS2. 
 
The protocol and amendments have been reviewed and approved by the UK 
National Research Ethics Service (London - Westminster committee; REC 
reference 10/H0802/46). The trial is carried out in accordance with the 
declaration of Helsinki and in keeping with Good Clinical Practice Guidelines. 
Registration was completed before recruitment commenced (NCT01920048) 
and ISRCTN45979711).  The first patient was randomized on 28th August 2013 
and at the time of this publication, 400 patients have been randomized. Figure 2 
summarizes the study timeline. There has been one major amendment to the 
protocol, implemented in July 2014, when the first inclusion criterion was 
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modified from “LVEF ≤30%” to “LVEF≤35%” to facilitate comparison with 
relevant literature and guidelines. At this stage, “≥CCS class 3 angina” was 
removed from the list of exclusion criteria, due to the difficulty in distinguishing 
angina from breathlessness in this particular population. 
 
Assessment of LV function and viability 
Suitability of patients on the basis of EF will be adjudicated by the participating 
centers, on the basis of recent echocardiography or MRI studies. All patients will 
also have echocardiography performed at randomization (if the qualifying EF 
was based on a recent echocardiogram, this can be submitted as the baseline 
study) as well as 6 and 12 months later. Baseline, 6 month and 12 month 
echocardiograms will be anonymized and submitted to an independent 
echocardiography core laboratory (at Guy’s and St Thomas’ Hospital, London, 
UK), which will determine LV volumes and EF using a biplane Simpson’s method, 
for evaluation of the major secondary outcome. The core laboratory will be 
blinded to treatment assignment as well as to the timing of the studies in relation 
to randomization. Core laboratory analysis will also include the degree of mitral 
regurgitation and segmental wall motion. 
 
Myocardial viability testing is used to prospectively predict hibernation by 
identifying the extent of fibrosis, contractile reserve, membrane integrity or 
metabolic activity(19).  There has never been a randomized evaluation of the 
value of viability testing in the management of ICM and observational series have 
reported seemingly conflicting results. A meta-analysis of over 3000 patients 
with ICM from 24 studies showed that mortality was lower following 
revascularization in patients with viable myocardium but that this benefit was 
not seen in the absence of viability(20). A more recent observational series of 
patients with ICM assessed by PET showed that revascularization was associated 
with lower mortality compared to OMT when the extent of viability exceeded 
more than 10% of the whole myocardium(21).  However, analysis of a subgroup 
of patients in the STICH trial who underwent discretionary viability testing, did 
not demonstrate an interaction between the response to revascularization and 
their viability classification(22). A pertinent consideration is the fact that the 
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STICH substudy classified patients dichotomously as having viable hearts or not. 
However, an individual with ICM usually has some regions that are clearly viable 
and others that are not and with PCI, it is possible to target revascularization to 
myocardial territories selected on this basis. Notwithstanding differences in 
sensitivity and specificity between imaging modalities, in order to ensure 
widespread applicability of trial results, segmental viability will be determined 
by any recognized modality in REVIVED. Imaging and intervention specialists at 
each participating center assess segmental viability and the feasibility of 
revascularizing the relevant segments, to determine whether an individual 
patient will be eligible for randomization.  
 
Percutaneous coronary intervention arm 
PCI will be performed according to local protocols. Dual antiplatelet therapy 
should be given in all cases, with pre-loading, and the post-PCI duration based on 
the individual’s bleeding risk and local/national guidelines. In general, drug-
eluting stents are recommended, but in patients who have an indication for long-
term formal anticoagulation (e.g. for concurrent atrial fibrillation, LV thrombus 
or venous thromboembolic disease), the choice of stent type should be based on 
their suitability for medium-term combined antiplatelet and anticoagulation 
therapy.  
 
Completeness of revascularization: it is strongly recommended that PCI be 
attempted on all significant coronary lesions in major proximal coronary vessels 
(or side branches >2.5mm in diameter) subtending viable myocardium. Lesion 
significance is defined as >70% diameter stenosis on angiography or for lesions 
between 50 and 70% diameter stenosis, when accompanied by demonstrable 
reversible ischemia on invasive or non-invasive testing.  Planned target lesions 
will need to be identified by the operator and recorded by the trial coordinator 
before the procedure.  Patients who meet inclusion criteria and have chronic 
total occlusion (CTO) of coronary arteries subtending viable myocardial 
segments should be considered for REVIVED, provided that the PCI operators 
predict a high likelihood of successfully reopening these vessels. It is 
recommended that dedicated CTO operators, in units that have this degree of 
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specialization, undertake such cases. The coronary disease burden at baseline 
and the completeness of final revascularization will be characterized by the 
BCIS-JS and Revascularization Index (RI), where RI = (JSpre – JSpost)/JSpre(18). The 
interaction between treatment effect and RI as well as the presence of a CTO will 
be the subject of a separate substudy. 
 
Staged PCI: a single stage strategy should be employed where possible. However, 
provisional staging could be considered in patients with renal dysfunction, 
complex coronary disease (including CTO) or if it is felt during PCI that deferring 
intervention to one or more vessels is in the patient’s best interests (e.g.  due to 
unexpected high contrast volumes or procedural complications during PCI to the 
first vessel). Staging must be prespecified at the index procedure. Urgent 
revascularization before the planned second stage procedure will be considered 
a secondary endpoint. 
 
Optimal medical therapy in both arms 
In order to ensure that patients in both arms of the trial receive optimal medical 
and device therapy, there is a nominated heart failure lead at each participating 
centre who is actively involved in patient selection and monitoring of therapy 
during the course of the trial. Furthermore, a trial Medical Therapy Committee 
has been established, that will review available evidence and guidelines at least 
annually and refine recommendations to ensure that drug and device therapy 
given to all patients in the trial remains optimal and contemporary. Each site is 
provided with a standard operating procedure for delivering and monitoring 
OMT, which sets out classes of drugs appropriate for trial patients, including HF 
therapies (such as angiotensin converting enzyme inhibitor or angiotensin 
receptor blocker +/- neprilysin inhibitor, betablocker and mineralocorticoid 
receptor antagonist (23)) and secondary prevention for atherosclerosis 
(including statin and antiplatelet agent) as well as recommended treatment 
targets (including lipid profile, HbA1c, resting heart rate). Formal 
anticoagulation for LV thrombus detected on imaging or as prophylaxis for 
severe LV dysfunction/ dyskinesis is at the discretion of the treating physician. 
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Initiation of the above treatments, dose-titration and relevant monitoring is per 
local HF protocols. 
 
Eligible patients are initiated on medical therapy prior to randomization and, in 
patients presenting with de novo HF, assessment of LV EF is deferred if they are 
not on appropriate medical therapy at presentation. Optimization of medical and 
device therapy will continue in both groups even after randomization, 
throughout the course of the trial.  
 
ICD implantation is not mandatory for inclusion in REVIVED, although many 
patients who fulfill trial eligibility criteria may also be candidates for primary 
prevention ICDs. Participating sites are encouraged to follow international 
guidelines(23)  when deciding on ICD or resynchronization device therapy and 
to make and document the decision to implant (or not implant) a device, before 
randomization.  
 
Statistical considerations 
Power Calculation: In the STICH trial, the rate of all cause death or hospitalization 
for HF at 5 years was 54% in the medical therapy group, with approximately 
50% of events occurring in the first year and a steady rate thereafter(7). These 
data are similar to the 1 year rates of death or HF hospitalization reported in 
registries of Western European populations(24). On this basis, the predicted 
occurrence of death or hospitalization for HF at two years is 36% in the OMT 
group. The primary outcome will be measured over the entire trial duration, 
with a minimum follow-up duration of two years. A trial of 700 (350 in each 
group), with 300 patients experiencing a primary outcome, would have over 
85% power to detect a hazard ratio of 0.7 (a 30% relative reduction in the 
hazard) at 5% significance, allowing for up to 5% losses by the end of follow-up. 
The hazard ratio of 0.7 is considered clinically meaningful and in line with the 
magnitude of benefit observed across other treatment modalities in this 
population. For the major secondary endpoint, even half this sample size will 
provide 90% power to detect a minimum difference in EF of 4%, assuming a 
standard deviation of 11%.  
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This trial will be a comparison of initial strategy, rather than technique; the 
projected event rates and hazard ratio allow for the fact that OMT patients may 
undergo subsequent revascularization. As such, no additional adjustments have 
been made to the power calculation to account for unplanned revascularization 
in the OMT arm. In patients assigned to receive OMT, revascularization by PCI or 
CABG during the trial would only be recommended in one of the following 
circumstances: readmission with an acute coronary syndrome (diagnosed on the 
basis of typical ischemic symptoms as well as a rise in cardiac biomarker levels 
or dynamic ST-segment deviation on ECG), deterioration in exertional angina to 
≥CCS class 3 symptoms or the occurrence of resistant ventricular arrhythmias 
considered to be ischemic in etiology.  
 
Statistical Analysis: A detailed statistical analysis plan will be finalized before any 
data are analyzed by treatment assignment. Analysis of outcomes will be by 
treatment assignment, on an intention-to-treat basis. An unadjusted time-to-
event analysis will be performed on the primary outcome using data across all 
follow-up, with time to the first event (or censoring) times measured from 
randomization. Hazard ratios together with associated confidence intervals will 
be calculated from the Cox proportional hazards model. Cumulative event rates 
will be calculated and presented using Kaplan-Meier time-to-event curves. As a 
measure of absolute treatment difference, cumulative event rates will be 
compared at 2 years. Each individual component of the primary composite 
outcome as well as other secondary time to event outcomes will be analyzed 
using the above methods. Losses to follow-up are expected to be minimal and 
patients will be included up until the time they experience the event or are 
censored. Any categorical outcome measures compared at specific time points 
will be examined using risk ratios and risk differences, confidence intervals and 
significance tests. Continuous variables will be analyzed and presented as mean 
treatment differences, confidence intervals and p-values derived from analysis of 
co-variance models or unpaired t-tests as appropriate (with appropriate 
transformation if necessary).  
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Interim analyses by treatment assignment are not planned. A limited number of 
subgroups analyses will be performed, which will be detailed in the analysis 
plan. A risk model will be developed, based on interactions between variables 
and treatment in the Cox model, and used to examine whether the impact of 
treatment depends on a person’s underlying risk.  
 
Health Economic Analysis 
The Centre for Health Economics at the University of York, UK will perform a 
formal health economic analysis. Data will be collected on health service 
resource use including length of inpatient stays, outpatient visits, use of primary 
care resources, use of cardiovascular medication and devices and subsequent 
cardiovascular procedures. Resource use will be valued in monetary terms using 
routine unit cost data relevant to the UK National Health Service (NHS).  These 
will include NHS Reference Costs, British National Formulary drug prices and the 
Personal Social Services Research Unit (PSSRU) survey of unit costs.   
A formal cost effectiveness of PCI in this population will be undertaken using a 
decision analytic framework, which will be a cohort model with states 
representing death and different levels of HF symptoms. Key features will 
include the quantification of health benefits in terms of quality-adjusted life 
years (QALYs) and the use of an NHS cost perspective. Standard decision rules 
will be used to assess cost effectiveness and extensive sensitivity analysis will be 
undertaken (probabilistic and deterministic) to assess the implications of 
uncertainty in the available evidence for cost-effectiveness. Heterogeneity in cost 
effectiveness between different sub-groups of patients will be assessed using 
methods consistent with those applied to clinical outcomes.   
 
Data Collection and Monitoring 
Each patient’s demographic details, medical history, electrocardiogram, routine 
blood results, cardiac medication, LVEF, viability assessment, ICD interrogation 
result (if applicable) and the BCIS-JS are recorded at baseline. LVEF will be 
reassessed at 6 and 12 months as detailed above. ICD interrogation, quality of 
life scores, BNP (or NT-Pro BNP) level, Troponin (T or I) level and cardiac 
medication are recorded at 6, 12 and 24 months post-randomization. All major 
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outcomes and Serious Adverse Events are collected at 6, 12 and 24 months for all 
patients and yearly thereafter for patients who have been randomized more than 
2 years before the end of the trial. Additionally, patients who undergo 
revascularization (by treatment assignment or as an unplanned procedure) have 
Troponin levels checked before and after the procedure. Hospitalization and 
mortality will be tracked using national databases to ensure that any unreported 
major outcome events are identified. The DMSC will review serious adverse 
events and any other trial safety issues. The Clinical Trial Unit collects a snapshot 
of screening, from each center, twice a year. Recruiting centers capture details of 
all patients with extensive CAD and EF ≤35% during this representative period. 
These data will be used to generate a Consort-style flowchart, describing the 
total population screened as well as the frequency and causes of patients 
excluded from the trial. 
 
Conclusion 
Ischemic cardiomyopathy is the commonest cause of HF and is associated with 
significant mortality and morbidity. Surgical revascularization has recently been 
shown to improve long-term outcomes in some patients, but surgery itself 
carries a major early hazard in this group. PCI is an appealing alternative to 
surgery, which may allow a better balance between risk and benefit, but this 
assertion has never been formally tested. REVIVED is the first randomized 
controlled trial of PCI for severe ischemic LV dysfunction and will provide 
important data that will inform guidelines on revascularization in ICM. 
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Figure 1: STUDY FLOW 
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Figure 2: STUDY TIMELINE 
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Figure 3: Trial Organization 
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Table 1. Studies of revascularization versus medical therapy 
published between 2002 and 2017 
 
 
Follow-up duration is quoted as mean ± SD or median (IQR).  
† RCTs, ‡ adjusted mortality/propensity matched data; NR: not reported 
(6, 7, 9, 21, 25-35) 
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Table 2. Definitions of outcome measures 
 
Acute Myocardial 
Infarction (MI) 
 
 
 
 
1. Spontaneous MI (≥48 hrs after PCI/CABG)  
Detection of a rise and/or fall of cardiac Troponin T or I levels, 
with at least one value higher than the 99th percentile upper 
reference limit (URL) AND symptoms consistent with 
ischaemia OR dynamic ECG changes  (including >1mm ST 
elevation, new Left Bundle Branch Block (LBBB) >1mm ST 
depression, >3mm T wave inversion)  
2. Peri-procedural MI (<48 hrs after PCI/CABG)* 
Following PCI, Troponin (T or I) > 5 x the 99th percentile 
URL) (or 5 x the baseline value if this is higher than the URL) 
in combination with any of (a) evidence of prolonged 
ischaemia (>20 min) as demonstrated by prolonged chest pain 
and/or ischaemic ST changes or (b) new pathological Q waves 
or (c) angiographic evidence of a flow limiting complication, 
such as of loss of patency of a side branch, persistent slow-
flow or no-reflow, embolisation, or (d) imaging evidence of 
new loss of viable myocardium or new regional wall motion 
abnormality. 
Following CABG, Troponin (T or I)  > 10 x 99th percentile URL 
(or 10 x the baseline value if this is higher than the URL) in 
combination with any of the following: (i) new pathological Q 
waves or (ii) angiographically documented new graft or new 
native coronary artery occlusion or (iii) imaging evidence of 
new loss of viable myocardium or new regional wall motion 
abnormality, 
3. Sudden death 
Cardiac arrest accompanied by new ST elevation/LBBB on 
ECG and/or evidence of fresh coronary thrombus at 
autopsy/angiography 
* In addition to classifying patients dichotomously, as having suffered 
a periprocedural MI or not on the basis of the 2012 Universal 
Definition of a type 4 MI(36), baseline and peak Troponin levels 
measured within 24 hours of a procedure will be recorded. This will 
provide a continuous outcome measure of periprocedural myocardial 
injury and will also allow subsequent reclassification in the event of 
further revisions to definitions of periprocedural MI that may occur 
during the course of the trial.. 
Appropriate ICD 
therapy 
At least one ICD shock or episode of anti-tachycardia pacing 
for documented ventricular tachycardia (VT) or ventricular 
fibrillation (VF)  
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Cardiovascular 
death 
All deaths where there is no clinical or post-mortem evidence 
of a non cardiovascular aetiology 
Hospitalization 
for heart failure 
(HF)(37). 
Hospital admission (lasting at least 24 hours) for deteriorating 
symptoms or signs of HF, where there is a documented 
diagnosis of HF and the patient receives initiation or 
intensification of treatment for HF. Initiation or intensification 
of treatment includes at least one of the following: increase in 
oral diuretic dose or addition of another oral diuretic, 
intravenous diuretic therapy, intravenous vasoactive therapy 
(vasodilator, inotrope or vasopressor), mechanical circulatory 
support (MCS) (including intra-aortic balloon pump, Impella, 
extra-corporeal membrane oxygenation) or cardiac 
transplantation. 
HF during or after the assigned PCI procedure itself is defined 
as prolongation of the planned admission by at least 24 hours 
due to acute heart failure requiring initiation or intensification 
of treatment as defined above. Prolongation of hospital 
admission in patients who have prophylactic pre-PCI insertion 
of a MCS should not be recorded as having a HF hospitalization 
unless there are features of HF requiring initiation or 
intensification of treatment as defined above. 
Elective admission for implantation or revision of ICD/cardiac 
resynchronization therapy (CRT) devices will not constitute a 
HF hospitalization endpoint.  
Major Bleeding Major bleeding will be defined using the Bleeding Academic 
Research Consortium (BARC) categories(38) below: 
Type 3a  
• Overt bleeding plus haemoglobin drop of ≥30 to 
<50g/L (provided haemoglobin drop is related to 
bleed) 
• Any transfusion with overt bleeding 
 
Type 3b 
• Overt bleeding plus haemoglobin drop ≥50g/L 
(provided haemoglobin drop is related to bleed) 
• Cardiac tamponade 
• Bleeding requiring surgical intervention for control 
(excluding dental/nasal/skin/haemorrhoid) 
• Bleeding requiring intravenous vasoactive drugs 
 
Type 3c 
• Intracranial haemorrhage (does not include 
microbleeds or haemorrhagic transformation; does 
include intraspinal) 
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• Subcategories; confirmed by autopsy or imaging or 
lumbar puncture 
• Intra-ocular bleed compromising vision 
 
Type 4: CABG-related bleeding 
• Perioperative intracranial bleeding within 48 hours 
• Reoperation following closure of sternotomy for the 
purpose of controlling bleeding 
• Transfusion of ≥ 5 units of whole blood or packed red 
blood cells within a 48 period 
• Chest tube output ≥ 2 L within a 24 h period 
• If a CABG-related bleed is not adjudicated as at least a 
Type 3 severity event, it will be classified as ‘not a 
bleeding event’ 
 
Type 5: fatal bleeding 
Type 5a 
• Probable fatal bleeding: no autopsy or imaging 
confirmation, but clinically suspicious 
Type 5b 
• Definite fatal bleeding: overt bleeding or autopsy or 
imaging confirmation 
 
Unplanned 
revascularisation 
PCI group: any unplanned target vessel or non-target vessel 
revascularisation by PCI or CABG following index PCI, 
excluding provisional staged PCI (with plan documented at the 
index procedure).  
OMT group: any revascularisation by PCI or CABG 
 
 
  
 
